Dairy cows infected with influenza A(H5N1) reveals low infectious dose and transmission barriers
This study challenges current hypotheses of H5N1 transmission on dairy farms, raising important questions about potential agent, host, or environmental cofactors contributing to viral spread.
WHO: New global youth competition on influenza and COVID-19 prevention and control
Submissions will open on Monday 3 August 2026, until Sunday 13 September 2026.
Interview: The evidence linking respiratory infections to cardiovascular disease is strong and growing
Prof Colin Russell, ESWI Chair and Co-Chair of the Steering Group on Prevention of Respiratory Infections, explains how a new Council Recommendation could enhance preventative health for at-risk groups.
TLR7 alters the maternal immune landscape during influenza A infection to increase maternal and fetal morbidity
Toll-like receptor 7 (TLR7) recognizes single-stranded RNA viruses, including IAV, yet its role in maternal immune responses and pregnancy outcomes during IAV infection is poorly understood.
Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta-Analysis
High-dose inactivated influenza vaccine (HD-IV) provides superior protection compared with SD-IV against P&I and all-cause hospitalisation in older adults, with the greatest benefits among younger seniors and those without cardiovascular disease.
Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults
A Cluster Randomized Crossover Study
Cross-reactive human antibody responses to H9N2 influenza virus, New York, United States, 2025
Assessed cross-reactive antibody responses to H9N2 viruses using a panel of recently collected human sera from the general population of a large metropolitan city in North America (New York City).
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study
Participants aged 3–8 years were randomised in a 1:1 ratio to receive the quadrivalent recombinant influenza vaccine (RIV4) or quadrivalent inactivated influenza vaccine (IIV4).